85 Minutes to Better Lives: Maxime Dely on the Power of Time in Photopheresis
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, posted on LinkedIn:
”85 minutes, no more, for an extracorporeal photopheresis procedure
Last week, during my final week at work, I accompanied a patient throughout her extracorporeal photopheresis session.
We talked, we shared a few stories… and suddenly, the end-of-procedure beep sounded.
Stopwatch in band: 85 minutes. No more
From the start of the procedure to disconnection. Ten minutes later, she was leaving in the ambulance.
Shorter than a football match or an old movie on TV.
For some, this time saving may seem small.
But for the patients’quality of life – and after hearing it directly from them – this gain is a big YES.
Extracorporeal photopheresis (ECP) is a technique used to treat certain immune diseases. It’s a demanding treatment – both medically and emotionally.
So why is this notion of time so important?
Because here, time saved is time given back.
In the centers where I’ve had the privilege to work and support the teams, online ECP has made it possible to save up to two hours compared with other so-called offline techniques.
It’s not just a technical achievement – it’s a real improvement in patient comfort.
An hour and a half less in the hospital means an hour and a half more at home, in one’s own environment, with one’s habits, comfort, and above all, close to loved ones.
And beyond the human benefit, this efficiency has a tangible impact:
- Better bed turnover,
- More available teams,
- And sometimes, one more treatment slot for another patient.
85 minutes, no more.
In photopheresis, as in many other areas of care, time itself is a form of healing.”

Keep up with Hemostasis Today.
-
Mar 16, 2026, 07:26James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data
-
Mar 14, 2026, 20:03Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency